Advertisement

Topics

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement

11:47 EDT 7 Aug 2018 | Investing News Network

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Neuren Pharmaceuticals (ASX:NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Neuren retains rights to develop and commercialize trofinetide for all indications outside of North America. As quoted in the press release: ACADIA … Continued

The post ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement appeared first on Investing News Network.

Original Article: ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement

NEXT ARTICLE

More From BioPortfolio on "ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...